The Securities and Exchange Commission filed charges on Eli Lilly and Co. yesterday for violations of the Foreign Corrupt Practices Act (FCPA) that allege the drug maker’s subsidiaries overseas bribed foreign officials in Russia, China, Brazil and Poland.
At the end of last month, the European Medicines Agency approved its budget and work program for the coming year, promising to implement measures to increase operational efficiency, enhance transparency and communication with stakeholders, and improve the quality and consistency of rulemaking.
A just-published report from the European taskforce trying to help Greece crawl out of its crisis makes clear just how significant a role health reform is supposed to play in restoring health to the economy.
With the general election behind us, the anticipated avalanche of ObamaCare regulations has begun. Last week, it was reported that more than 13,000 pages of rules and regulations have been issued by HHS since Nov. 6th
Hindsight can be a great teacher – but only if you have the self-awareness needed to adapt those learnings to the next business challenge, whose rough edges are by definition almost always “non-recurring.”
Participants in the 23rd Annual NYPF General Assembly last Friday outlined the many challenges facing industry, and the importance of collaboration as a way to move forward.
The National Intelligence Council’s Global Trends Report explains the scenarios in which the next 18 years may play out internationally.
Yesterday Acura Pharmaceuticals launched its new pseudoephedrine-based product Nexafed, an over-the-counter product aimed at deterring abuse of the illicit drug methamphetamine.
The Puzzle Master
The pharmaceutical industry’s global reputation is on the mend, even if some countries – notably China – are more hostile, according to the latest Ipsos Reputation Snapshot for the Pharmaceutical Sector, from the Ipsos Global Reputation Centre.
Price Waterhouse Cooper’s “Pharma 2020: From vision to decision” parses a mix of gloomy and glowing scenarios that reflect the fickle, delicate nature of today’s industry.
Given the amount of activity in the hepatitis C drug development space – as evidenced in PharmExec’s 2013 Pipeline report – patients are scouring the internet for information on the disease, available treatments, and soon to be available treatments.
Greece took its part on Wednesday in the latest widespread strikes against austerity measures that swept across Europe.
In the wake of the meningitis outbreak caused by contaminated compounded medications produced by the New England Compounding Center (NECC).
How can the emerging field of data science help to fruitfully translate research and discovery into successful drug development.
With the Presidential election decided and President Obama the clear winner, it’s time for Pharma to get down to business on the implementation of ObamaCare.
The pharmaceutical industry as of late has faced a growing movement against patent protection in favor of providing access to low cost medicines, specifically in developing countries.
Pharm Exec's 2013 Pipeline Report
Providers and patients fish for that delicate balance between access and abandonment.
Prix Galien celebrates a new round of next generation drug technologies.
Pharmaceutical industry leaders Novartis and Merck-among others-released second-quarter 2012 results showing global sales down in third-quarter 2012, with growth in key pharmaceutical products helping to offset losses due to patent expirations.
Global Launch in the IMS Health Era
The sudden departure of EC Health Commissioner John Dalli tops an already difficult year for the European pharma regulators, writes Reflector.
No doubt the November 6th election is going to be close, very close: close for the Presidency, close for the Senate, and possibly close for the House.
Just days before the reports that R&D investment in Spanish pharma had fallen to below EUR1 billion ($1.3 billion) in 2011 for the first time since 2007.
Grey Healthcare Group - Leveraging Your Brand’s Name to Achieve Post-Patent Success
Ethics is a matter of trust, which in the regulatory space requires transparency and openness among all stakeholders, including patients and industry.
Featured panelists at ExL’s annual Digital Pharma East conference this week included practicing physicians, vocal ePatients, social media gurus and digital marketing consultants with plenty of hours logged in big pharma boardrooms.
